Conference Coverage Alemtuzumab’s Benefits May Be Sustained for Three Years in Patients With MS Read More
Conference Coverage Clinical and Subclinical Factors Strongly Influence MS Treatment Decisions Read More
Conference Coverage Ofatumumab Reduces New Gadolinium-Enhancing Lesions With Partial B Cell Depletion Read More
Conference Coverage High BMI and Weight in Young Adulthood Are Linked to Younger Age of MS Symptom Onset Read More
Conference Coverage A Personalized Management Plan of Fingolimod Titration May Benefit Some Patients With MS Publish date: June 2, 2014 Read More
